When the Senate reconvenes after the July 4th recess, here

New Post Public Reply Private Reply Replies (1) Message Board
CyberC
511
When the Senate reconvenes after the July 4th recess, here we go:

Posted On: 06/30/2019 3:18:29 PM
Avatar
Posted By: gimli
https://www.ipwatchdog.com/2019/06/30/patent-...id=110847/

June 30, 2019

Senator Thom Tillis
Chair, Senate IP Subcommittee
113 Dirksen Senate Office Building
Washington, DC 20510

Senator Chris Coons
Ranking Member, Senate IP Subcommittee
218 Russel Senate Office Building
Washington, DC 20510

Representative Doug Collins
Ranking Member, House Judiciary Committee
1504 Longworth House Office Building
Washington, DC 20515

Representative Hank Johnson
Chair, House IP Subcommittee
2240 Rayburn House Office Building
Washington, DC 20510

Representative Steve Stivers
2234 Rayburn House Office Building
Washington, DC 20515

RE: Patent Eligibility

Dear Senator Tillis, Senator Coons, Representative Collins, Representative Johnson and Representative Stivers:

We applaud your efforts over the last several months to engage stakeholders on the important issue of patent eligibility reform. We view this effort as critical for the future of a variety of high-tech and life sciences industries in the United States.

As was discussed during testimony in recent hearings of the Senate IP Subcommittee, the Supreme Court has refused four (4) dozen petitions for certiorari on the issue of patent eligibility since issuing its decision in in Alice Corp. v. CLS Bank Int’l, 134 S.Ct. 2347 (2014). The assumption must, therefore, be that the Supreme Court is content with its patent eligibility jurisprudence.

Unfortunately, Supreme Court jurisprudence on patent eligibility is irreconcilable and has created tremendous uncertainty in an area where long term certainty is absolutely essential. Innovation typically takes a great deal of time, and commercializing that innovation takes even more time. Without long term stability and predictability investment decisions and incentives become skewed.

The United States Court of Appeals for the Federal Circuit has explained in at least several decisions that they feel handcuffed by Supreme Court jurisprudence. But even more problematic is the wide divergence of outcomes among Federal Circuit panels. Put simply, the Supreme Court test for patent eligibility is subjective and unpredictable. Congress must act.

Amidst this uncertainty, and with the fifth anniversary of the Supreme Court’s Alice decision having just passed, last week IPWatchdog.com held a two-day symposium to discuss the state of patent eligibility in the United States. During this symposium overwhelming consensus was achieved by the Patent Masters™ faculty and symposium attendees on a variety of principles and recommendations.

The following statements received unanimous consent during the Patent Masters™ Symposium:

Supreme Court decisions interpreting 35 U.S.C. 101 have harmed the U.S. economy.
Supreme Court decisions interpreting 35 U.S.C. 101 are impeding the progress of the useful arts.
Supreme Court decisions interpreting 35 U.S.C. 101 are impeding the progress of innovations relating to medical diagnostics.
Supreme Court decisions interpreting 35 U.S.C. 101 are impeding the progress of innovations relating to important areas of software innovations, such as artificial intelligence and machine learning.
Supreme Court decisions interpreting 35 U.S.C. 101 have diminished America’s global competitiveness.
The Supreme Court was unquestionably incorrect in AMP v. Myriad Genetics when they said discoveries are not patent eligible. The Constitution explicitly says otherwise, as does 35 U.S.C. 101.
The following statements achieved consent from at least eighty-percent (80%) of those attending the symposium:

The Supreme Court’s decisions on patent eligibility in Funk Brothers, Benson, Flook, Diehr, Chakrabarty, Bilski, Mayo, Myriad and Alice are hopelessly irreconcilable. [91% consensus]
Supreme Court decisions interpreting 35 U.S.C. 101 are driving innovation and investment overseas. [86% consensus]
Supreme Court decisions interpreting 35 U.S.C. 101 violate separation of powers by adding “judicial exceptions” and usurping Congressional authority to define what is patent eligible. [83% consensus]
The 2019 Revised Patent Subject Matter Eligibility Guidance published by the USPTO creates the proper analytical framework for approaching questions of patent eligibility. [82% consensus]
Therefore, it is the recommendation of the undersigned attendees of the Patent Masters™ Symposium that:

Congress should legislatively overrule Alice v. CLS Bank.
Congress should legislatively overrule Mayo v. Prometheus.
Congress should explicitly prohibit “judicial exceptions” to patent eligibility.
In conclusion, we greatly appreciate your work on this important matter, and we enthusiastically support your efforts. We stand ready to help in any way possible. Strengthening the U.S. patent system for future generations is of paramount importance.

Very truly yours,

Eugene R. Quinn, Jr., President & CEO, IPWatchdog, Inc.

Paul Michel, Retired Chief Judge, U.S. Court of Appeals for the Federal Circuit

cc: Andrei Iancu, Director of the USPTO



Meredith Addy, Partner, AddyHart, P.C.

James Carmichael, Carmichael IP

Brad Close, Executive Vice President, Transpacific IP

Nicholas D’Andrea, Patent Agent

Kate Gaudry, PhD, Patent Attorney (on behalf of herself)

Robert Greenspoon, Founding Partner, Flachsbart & Greenspoon, LLC

Chris Israel, Executive Director, Alliance for U.S. Startups and Inventors for Jobs

Efrat Kasznik, President, Foresight Valuation Group, LLC

Sherry Knowles, Principal, Knowles Intellectual Property Strategies, LLC

Jack Lu, Founding Partner and Chief Economist, IPMAP LLC

Lissi Mojica, Managing Director, Answers IP, LLC

Mark Nowatarski, Principal, Markets, Patents & Alliances, LLC

Isaac T. Slutsky, Shareholder, Brooks Kushman

Bernard Tomsa, Shareholder, Brooks Kushman

John White, Partner, Berenato & White, LLC


Read More: https://investorshangout.com/post/view?id=547...z5sRmT73Av

Zerify Inc (ZRFY) Stock Research Links

ZRFY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

USDA Under Scrutiny as ASPCA Reports on Puppy Mill Violations

Updated Category News Views 322

ASPCA's Shocking Report on Puppy Mill Violations In a recent analysis by the ASPCA, alarming statistics have surfaced regarding animal welfare violations at USDA-licensed commercial dog breeding facilities. The findings reveal that in a given year, substantial breaches of care standards were documented, yet no actions were taken to ensure the safety of the animals....

Continue Reading
PowerReviews Unveils Partner Program to Amplify UGC Value

Updated Category News Views 1653

PowerReviews Launches Comprehensive Partner Program PowerReviews, a reputable name backed by 1WorldSync, has initiated an exciting Partner Program aimed at revolutionizing the way user-generated content (UGC) is leveraged. This initiative is designed to not only boost productivity but also facilitate enhanced revenue opportunities for partners who promote its advanced...

Continue Reading
Turnspire Capital Partners Expands Portfolio with GHP Group

Updated Category News Views 81

Turnspire Capital Partners pulled the trigger on acquiring GHP Group back in 2024, a move that sent shockwaves through the consumer product landscape. This was no random buy; GHP's got its fingers in the pie of outdoor living products—think patio heaters and grills—all under reputable brands like Dyna-Glo and Pleasant Hearth. GHP Group: A Heavyweight Player in Outdoor...

Continue Reading
MPI Corporation Launches Groundbreaking 250 GHz Probe System

Updated Category News Views 187

Enhancing Precision in Semiconductor Testing In the fast-evolving world of semiconductor technology, precision and performance are critical. MPI Corporation has once again demonstrated its innovative spirit by unveiling a revolutionary 250 GHz broadband test solution. This state-of-the-art system combines the power of the TITAN™ Probes and MPI's extensive expertise in...

Continue Reading
Passage Bio's Gene Therapy Strategy: Hope for Dementia Treatments

Updated Category News Views 76

Promising Advances in Gene Therapy Recently, Passage Bio, Inc. (NASDAQ: PASG), a pioneering company in genetic medicine, showcased groundbreaking preclinical and interim clinical results for its gene therapy product, PBFT02. This was presented at a major congress focused on gene and cell therapy. Designed specifically to target frontotemporal dementia associated with GRN...

Continue Reading